natgillin/translations-raw huggingface dataset:
Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. 
Kronični artritis so povezovali z okužbo z divjim sevom rdečk in je bil povezan z izolacijo perzistentnega virusa in/ali virusnega antigena iz telesnih tkiv.
Other than the increase in febrile seizure after the first dose, no safety concerns after the first or second dose were identified. 
Razen povečanja pojavnosti vročinskih krčev po prvem odmerku niso odkrili nobenih drugih varnostnih zadržkov po prvem ali drugem odmerku.
Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk; however, transmission of the rubella vaccine virus to infants via breast milk has been documented without any evidence of clinical disease (see section 4.6). 
Zato se prenos s tesnim osebnim stikom, ki je teoretično možen, ne smatra za pomembno tveganje; dokumentirali pa so prenos cepilnega virusa rdečk na dojenčka z materinim mlekom, brez kliničnih znakov bolezni (glejte poglavje 4.6).
3) Produced in human diploid cells (MRC-5). 
3) Pridobljen iz humanih diploidnih celic (MRC-5).
Administration of immune globulins concomitantly with ProQuad may interfere with the expected immune response. 
Dajanje imunoglobulinov sočasno s cepivom ProQuad lahko ovira pričakovani imunski odziv.
• Rare (may affect up to 1 in 1,000 people): bronchiolitis (difficulty breathing with or without cough); unsteadiness with walking. 
• Redki (pojavijo se lahko pri največ 1 od 1.000 oseb): bronhiolitis (težave z dihanjem s kašljanjem ali brez); nemirnost pri hoji.
Persons who are breast-feeding or who intend to breast-feed should tell the doctor. 
Ženske, ki dojijo ali nameravajo dojiti, morajo to povedati zdravniku.
Furthermore, pregnancy should be avoided for 1 month following vaccination (see section 4.6). 
Poleg tega ženska 1 mesec po cepljenju ne sme zanositi (glejte poglavje 4.6).
• Individuals 12 months of age and older 
• Posamezniki, stari 12 mesecev ali več
The vaccine contains 16 mg of sorbitol. 
To cepivo vsebuje 16 mg sorbitola.
It is preferred that the second dose be administered within three months following the first dose. 
Najbolje je, da cepljena oseba dobi drugi odmerek v treh mesecih po prvem odmerku.
• Individuals between 9 and 12 months of age Immunogenicity and safety data show that ProQuad can be administered to individuals between 9 and 12 months of age, under special circumstances (e.g., in accordance with official recommendations or when early protection is considered necessary). 
Podatki o imunogenosti in varnosti kažejo, da se v posebnih primerih lahko s cepivom ProQuad cepi posameznike, stare od 9 do 12 mesecev (npr. v skladu z uradnimi priporočili ali kadar je nujna zgodnja zaščita).
1) Produced in chick embryo cells. 
1) Pridobljen iz celic piščančjih zarodkov.
2) Produced in human diploid lung (WI-38) fibroblasts. 
2) Pridobljen iz humanih diploidnih pljučnih (WI-38) fibroblastov.
What ProQuad is and what it is used for What you need to know before you receive ProQuad How to use ProQuad 
Kaj je cepivo ProQuad in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli cepivo ProQuad Kako uporabljati cepivo ProQuad Možni neželeni učinki
Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic system. 
Krvne diskrazije, levkemija, katera koli vrsta limfoma ali druga maligna novotvorba, ki vpliva na hematopoetski in limfatični sistem.
After reconstitution, use immediately or within 30 minutes if stored between 20°C and 25°C. 
Po pripravi uporabite takoj ali v 30 minutah, če ste pripravljeno cepivo hranili pri temperaturi od 20 ºC do 25 ºC.
In a study comparing 1 dose (N=1114) to 2 doses (N=1102) of Varicella Vaccine live (Oka/Merck), the estimated vaccine efficacy against all severities of varicella disease for the 10-year observation period was 94% for 1 dose and 98% for 2 doses (p<0.001). 
V študiji, ki je primerjala 1 odmerek (n = 1.114) z 2 odmerkoma (n = 1.102) cepiva z živim virusom noric (Oka/Merck), je ocenjena učinkovitost cepiva proti vsem stopnjam noric v 10-letnem opazovalnem obdobju znašala 94 % za 1 odmerek in 98 % za 2 odmerka (p < 0,001).
The results of a retrospective case-controlled study conducted by the US Centers for Disease Control and Prevention show that the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its inherent risk of SSPE. 
Rezultati retrospektivne študije primerov in kontrol (case-control study), ki so jo izvedli v Centrih za nadzor in preprečevanje bolezni (Centers for Disease Control and Prevention) v ZDA, kažejo, da je skupni učinek cepljenja proti ošpicam zaščita pred SSPE, ker preprečuje ošpice in tveganje za SSPE ob njih.
Solvent Water for injections. 
Vehikel voda za injekcije
Although a causal relationship between other strains of mumps vaccine and aseptic meningitis has been shown, there is no evidence to link Jeryl Lynn™ mumps vaccine to aseptic meningitis. 
Čeprav je bila dokazana vzročna povezava med drugimi sevi cepiva proti mumpsu in aseptičnim meningitisom, ni dokazov o povezavi cepiva proti mumpsu Jeryl Lynn™ z aseptičnim meningitisom.
ProQuad is not contraindicated in individuals who are receiving topical or low-dose parenteral corticosteroids (e.g. for asthma prophylaxis or replacement therapy). 
Cepivo ProQuad ni kontraindicirano pri osebah, ki dobivajo topične ali majhne parenteralne odmerke kortikosteroidov (npr. kot profilakso astme ali kot nadomestno zdravljenje).
The physician should be alert to the temperature elevation that may occur following vaccination (see section 4.8). 
Zdravnik mora biti pozoren na morebiten porast temperature po cepljenju (glejte poglavje 4.8).
Other medicines and ProQuad 
Druga zdravila in cepivo ProQuad
Severe humoral or cellular (primary or acquired) immunodeficiency, e.g., severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infection or an age-specific 
Huda humoralna ali celična (primarna ali pridobljena) imunska pomanjkljivost, npr. huda kombinirana imunska pomanjkljivost, agamaglobulinemija in AIDS ali simptomatska okužba s HIV
Vaccination should be deferred for at least 3 months following blood or plasma transfusions, or administration of immune globulins (IG). 
Cepljenje je treba odložiti za vsaj 3 mesece po transfuziji krvi ali plazme ali prejemu imunoglobulinov (IG).
Individuals less than 12 months of age who are vaccinated with a measles-containing vaccine during measles outbreaks or for other reasons may fail to respond to the vaccine due to the presence of circulating antibodies of maternal origin and/or immaturity of the immune system (see sections 4.2 and 5.1). 
Pri posameznikih, mlajših od 12 mesecev, ki so zaradi izbruha ošpic ali drugih razlogov cepljeni s cepivom, ki vsebuje virus ošpic, lahko zaradi prisotnosti materinih protiteles v obtoku in/ali nezrelosti imunskega sistema ne pride do odziva na cepivo (glejte poglavji 4.2 in 5.1).
Store and transport refrigerated (2°C-8°C). 
Cepivo shranjujte in prevažajte na hladnem (2 °C - 8 °C).
Once vaccinated, the person vaccinated should attempt to avoid for up to 6 weeks following vaccination, whenever possible, close association with the following individuals: 
Do 6 tednov po cepljenju naj se cepljena oseba, če je le mogoče, skuša izogniti tesnemu stiku z naslednjimi osebami:
This vaccine contains a trace amount of neomycin. 
To cepivo vsebuje neomicin v sledeh.
In combined clinical trials of a single dose of Varicella Vaccine live (Oka/Merck) in healthy children, the protective efficacy of the vaccine against all severities of varicella disease ranged from 81% to 100%. 
V kombiniranih kliničnih preskušanjih enkratnega odmerka cepiva z živim virusom noric (Oka/Merck) pri zdravih otrocih je znašala učinkovitost zaščite cepiva proti vsem stopnjam noric od 81 % do 100 %.
Over the entire follow-up, the incidence of varicella was approximately 10-fold lower among vaccinees than among children of the same age in the pre-vaccine era (estimated vaccine effectiveness over the study period was between 73% and 90%). 
Tekom spremljanja je bila pojavnost noric približno 10-krat nižja pri cepljenih otrocih kot pri enako starih otrocih iz obdobja pred cepivom (ocenjena učinkovitost cepiva v času študije je bila med 73 % in 90 %).
Manufacturer Responsible for Batch Release: Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031 BN Haarlem, The Netherlands 
Izdelovalec zdravila, odgovoren za sproščanje serij: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Nizozemska
Withdraw the entire content of the reconstituted vaccine from the vial into the same syringe and inject the entire volume. 
Celotno vsebino pripravljenega cepiva iz viale povlecite v isto brizgo in injicirajte celotno količino.
ProQuad is available in pack of 1, 10 and 20. 
Cepivo ProQuad je na voljo v pakiranjih po 1, 10 in 20.
The post-dose 2 geometric mean titres (GMTs) against mumps, rubella, and varicella were comparable across all age categories, while the GMTs against measles were lower in subjects who received the first dose at 9 months of age as compared to subjects who received the first dose at 11 or 12 months of age. 
Geometrične sredine titrov (GMT - geometric mean titres) proti mumpsu, rdečkam in noricam so bile po 2. odmerku primerljive za vse starostne skupine, medtem ko so bile GMT proti ošpicam nižje pri osebah, ki so prvi odmerek prejele v starosti 9 mesecev, v primerjavi z osebami, ki so prvi odmerek prejele v starosti 11 ali 12 mesecev.
Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g. hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions. 
Osebe z anamnezo anafilaktične, anafilaktoidne ali druge takojšnje reakcije (npr. koprivnica, oteklina ust in grla, težave pri dihanju, hipotenzija ali šok) po zaužitju jajc imajo lahko večje tveganje za takojšnje preobčutljivostne reakcije.
The overall safety profile of ProQuad was comparable whether it was administered concomitantly or alone. 
Celotni varnostni profil cepiva ProQuad je bil primerljiv ne glede na to, ali se je cepivo uporabljalo samo ali sočasno z drugimi cepivi.
Postdose 1 Postdose 2 
Po 1. odmerku Po 2. odmerku
Arthralgia and/or arthritis 
Artralgija in/ali artritis
In the first study, a long-term prospective cohort study, approximately 7,600 children vaccinated in 1995 with varicella vaccine in their second year of life were actively followed for 14 years in order to estimate the occurrence of varicella and herpes zoster. 
V prvi, dolgoročni prospektivni kohortni študiji so leta 1995 približno 7.600 otrok cepili s cepivom proti noricam v drugem letu starosti in jih potem aktivno spremljali 14 let, da bi ugotovili pojav noric ali pasovca.
ProQuad has not been evaluated for potential to impair fertility. 
Pri cepivu ProQuad niso ovrednotili možnosti za škodljiv vpliv na plodnost.
After reconstitution, the vaccine should be used immediately. 
Cepivo je treba uporabiti takoj po pripravi.
These data also suggest that varicella vaccination may reduce the risk of herpes zoster in vaccinated individuals. 
Ti podatki nakazujejo tudi, da cepljenje proti noricam lahko zmanjšuje tveganje za pojav pasovca pri cepljenih posameznikih.
Also, if the person to be vaccinated has already been exposed to the measles, mumps, rubella, or varicella virus but is not yet ill, ProQuad may not be able to prevent the illness from appearing. 
Če je bila oseba, ki bo cepljena, že izpostavljena virusu ošpic, mumpsa, rdečk ali noric, ni pa še zbolela, cepivo ProQuad morda ne bo moglo preprečiti pojava bolezni.
• If the person to be vaccinated has a family history of congenital or hereditary immunodeficiency, unless the immune competence of this person is demonstrated. 
• Če ima oseba, ki naj bi bila cepljena, v družini prirojeno ali dedno imunsko pomanjkljivost, razen če je bila dokazana imunska sposobnost te osebe.
The vaccine is a powder for suspension for injection contained in a single-dose vial, which should be mixed with solvent provided with the vial of powder. 
Cepivo je prašek za suspenzijo za injiciranje v enoodmerni viali, ki ga je treba zmešati z vehiklom, priloženim viali s praškom.
The potential risk-to-benefit ratio should be carefully evaluated before considering vaccination in such cases. 
V takih primerih je treba pred odločitvijo za cepljenje skrbno oceniti morebitno tveganje in korist.
Breakthrough varicella and zoster cases were usually mild. 
Izbruhi noric in pasovca so bili običajno blagi.
The preferred injection sites are the anterolateral area of the thigh in younger children and the deltoid area in older children, adolescents, and adults. 
Najprimernejše mesto za injiciranje je pri mlajših otrocih anterolateralno področje stegna, pri starejših otrocih, mladostnikih in odraslih pa področje deltoidne mišice.
Due caution should be employed in the administration of ProQuad to persons with individual or family history of convulsions, or a history of cerebral injury. 
Ustrezna previdnost je potrebna, kadar s cepivom ProQuad cepimo osebe z osebno ali družinsko anamnezo konvulzij ali anamnezo poškodbe možganov.
Clinical trials involving 6987 subjects who received ProQuad demonstrated detectable immune responses to measles, mumps, rubella, and varicella in a high proportion of individuals. 
Klinična preskušanja pri 6.987 preiskovancih, ki so dobili cepivo ProQuad, so dokazala zaznaven imunski odziv na ošpice, mumps, rdečke in norice pri velikem deležu posameznikov.
Dose 1 at 11 months / Dose 2 at 14 months N = 480 
1. odmerek pri 11 mesecih / 2. odmerek pri 14 mesecih n = 480
EU/1/05/323/001 EU/1/05/323/002 EU/1/05/323/003 EU/1/05/323/004 EU/1/05/323/005 EU/1/05/323/006 EU/1/05/323/007 EU/1/05/323/008 EU/1/05/323/009 EU/1/05/323/010 EU/1/05/323/011 EU/1/05/323/012 EU/1/05/323/013 
EU/1/05/323/003 EU/1/05/323/004 EU/1/05/323/005 EU/1/05/323/006 EU/1/05/323/007 EU/1/05/323/008 EU/1/05/323/009 EU/1/05/323/010 EU/1/05/323/011 EU/1/05/323/012 EU/1/05/323/013
BOX 581, 2003 PC Haarlem The Netherlands 
2031 BN Haarlem P.O. BOX 581, 2003 PC Haarlem Nizozemska
The seroprotection rates to measles, mumps, rubella, and varicella 6 weeks post-dose 1 and 6 weeks post-dose 2, for the Full Analysis Set are given in the following table. 
Stopnje serozaščite proti ošpicam, mumpsu, rdečkam in noricam 6 tednov po 1. odmerku in 6 tednov po 2. odmerku so podane za popolno analizo v naslednji preglednici.
High-risk individuals susceptible to varicella include: 
Osebe z velikim tveganjem, sprejemljive za norice, so:
Additionally, live measles vaccine and live mumps vaccine are produced in chick embryo cell culture. 
Živo cepivo proti ošpicam in živo cepivo proti mumpsu sta pridobljena iz celičnih kultur piščančjih zarodkov.
Dose 1 at 9 months / Dose 2 at 12 months N = 527 
1. odmerek pri 9 mesecih / 2. odmerek pri 12 mesecih n = 527
Both fever and measles-like rash usually occurred within 5 to 12 days following the vaccination, were of short duration and resolved with no long-term sequelae. 
Oba, zvišana telesna temperatura in ošpicam podoben izpuščaj, sta se pojavila večinoma v 5 do 12 dneh po cepljenju, bila kratkotrajna in izginila brez dolgoročnejših posledic.
Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine. 
Pri otrocih, ki se zdravijo zaradi tuberkuloze, po cepljenju z živim cepivom proti virusu ošpic ni prišlo do poslabšanja bolezni.
Experience with the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. demonstrates that antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination. 
Izkušnje s cepivom proti ošpicam, mumpsu in rdečkam, ki ga izdeluje Merck & Co., Inc., kažejo, da so protitelesa proti virusom ošpic, mumpsa in rdečk pri večini oseb zaznavna še 11 do 13 let po primarnem cepljenju.
History of hypersensitivity to any varicella vaccine or measles, mumps, or rubella vaccine, to any of the excipients, or to neomycin, which may be present as trace residues (see sections 2, 4.4 and 6.1). 
Preobčutljivost v preteklosti na katero koli cepivo z virusom noric ali cepivo proti ošpicam, mumpsu ali rdečkam, za katero koli pomožno snov ali za neomicin, ki je lahko prisoten v sledeh (glejte poglavja 2, 4.4 in 6.1).
As with other vaccines, ProQuad may not completely protect all persons who are vaccinated. 
Tako kot druga cepiva tudi cepivo ProQuad ne pomeni popolne zaščite vseh cepljenih oseb.
What ProQuad looks like and contents of the pack 
Izgled cepiva ProQuad in vsebina pakiranja
Studies have shown that breast-feeding postpartum women vaccinated with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants. 
Študije so pokazale, da lahko doječe matere, ki so bile po porodu cepljene z živim oslabljenim cepivom proti rdečkam, izločajo virus v mleku in ga prenesejo na dojenčke.
Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination with ProQuad (see section 4.4). 
Prejemniki cepiva naj se vsaj 6 tednov po cepljenju s cepivom ProQuad izogibajo uporabi salicilatov (glejte poglavje 4.4).
ProQuad contains sorbitol. 
Cepivo ProQuad vsebuje sorbitol
ProQuad should be injected into the muscle or under the skin either in the area of the outer thigh or of the upper arm. 
Cepivo se injicira v mišico ali pod kožo, v predel zunanje strani stegna ali nadlakti.
In these studies seroconversion in response to vaccination against measles, mumps, and rubella paralleled protection from these diseases. 
V teh študijah je bila serokonverzija kot odziv na cepljenje proti ošpicam, mumpsu in rdečkam vzporedna zaščiti po preboleli bolezni.
Immune system disorders Hypersensitivity 
Bolezni imunskega sistema preobčutljivost redki
If you have been told by your doctor that you or your child has an intolerance to some sugars, inform your doctor before you or your child receive this vaccine. 
Če vam je zdravnik povedal, da vi ali vaš otrok ne prenašate nekaterih sladkorjev, se pred cepljenjem s tem cepivom posvetujte z zdravnikom.
In comparison, following ProQuad given concomitantly with Prevenar and/or hepatitis A vaccine in 3 clinical trials, the observed rates of reported fever (≥39.4°C rectal equivalent) ranged from 15.2% to 27.2%. 
Po sočasni uporabi cepiva ProQuad in cepiva Prevenar in/ali cepiva proti hepatitisu A pa je v 3 kliničnih preskušanjih opazovani delež zvišane telesne temperature (ekvivalentno ≥ 39,4 °C rektalno) znašal od 15,2 % do 27,2 %.
ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles; see sections 4.2, 4.4, and 5.1). 
S cepivom ProQuad se lahko v posebnih primerih cepi posameznike, starejše od 9 mesecev (npr. v skladu z nacionalno shemo cepljenja, v primeru izbruha bolezni ali potovanja na področje z visoko prevalenco ošpic; glejte poglavja 4.2, 4.4 in 5.1).
The fever rate in all eight studies was lower after the second dose than after the first dose. 
Delež zvišane telesne temperature je bil v vseh osmih študijah po drugem odmerku manjši kot po prvem.
In the Full Analysis Set (vaccinated subjects regardless of their antibody titre at baseline), high seroprotection rates of >99% were elicited to mumps, rubella, and varicella post-dose 2, regardless of the age of the vaccinees at the first dose. 
V popolni analizi (cepljenih oseb, ne glede na njihov izhodiščni titer protiteles) so bile proti mumpsu, rdečkam in noricam po 2. odmerku dosežene visoke stopnje serozaščite > 99 %, ne glede na starost preiskovancev ob prejetju prvega odmerka.
If the person to be vaccinated has experienced any of the following, talk to the doctor or pharmacist before ProQuad is given: 
Če je pri osebi, ki naj bi bila cepljena, prišlo do katerega koli od naštetih pojavov, o tem pred cepljenjem s cepivom ProQuad povejte zdravniku ali farmacevtu:
Dose 1 at 12 months / Dose 2 at 15 months N = 466 
1. odmerek pri 12 mesecih / 2. odmerek pri 15 mesecih n = 466
Regarding herpes zoster, there were fewer herpes zoster cases among varicella vaccinees during the follow-up period than expected from rates in children of the same age with prior wild-type varicella during the pre-vaccine era (relative risk = 0.61, 95% CI 0.43 - 0.89). 
Glede pasovca pa je bilo med otroci, cepljenimi s cepivom proti noricam, manj primerov, kot bi jih pričakovali glede na odstotek pri enako starih otrocih, ki so preboleli divji tip noric v obdobju pred cepivom (relativno tveganje = 0,61; 95 % IZ: 0,43 - 0,89).
Although ProQuad contains live viruses, they are too weak to cause measles, mumps, rubella, or varicella (chickenpox) in healthy people. 
Čeprav cepivo ProQuad vsebuje žive viruse, so ti prešibki, da bi povzročili ošpice, mumps, rdečke ali norice (varičelo) pri zdravih ljudeh.
Active surveillance data in children vaccinated with Varicella Vaccine live (Oka/Merck) and followed for 14 years after vaccination showed no increase in the frequency of herpes zoster compared to children with prior wild-type varicella during the pre-vaccine era. 
Podatki stalnega spremljanja otrok, cepljenih z živim cepivom proti noricam (Oka/Merck) in potem spremljanih 14 let po cepljenju, niso pokazali nobenega povečanja pojavnosti pasovca v primerjavi z otroki, ki so predhodno preboleli divji tip noric v obdobju pred cepivom.
If a tuberculin test is to be performed, it should be done either any time before, simultaneously with, or 4 to 6 weeks after vaccination with ProQuad. 
Če je potreben tuberkulinski test, ga je treba opraviti kadar koli pred cepljenjem s cepivom ProQuad, hkrati z njim ali 4 do 6 tednov po njem.
Following a single dose of ProQuad, the vaccine response rates were 97.7% for measles, 96.3% to 98.8% for mumps, and 98.8% for rubella. 
Po enem odmerku cepiva ProQuad je znašal delež odziva na cepljenje 97,7 % za ošpice, 96,3 % do 98,8 % za mumps ter 98,8 % za rdečke.
Efficacy of the measles, mumps, and rubella components of ProQuad was previously established in a series of double-blind controlled field trials with the monovalent vaccines manufactured by Merck & Co., Inc., which demonstrated a high degree of protective efficacy. 
Učinkovitost komponent cepiva ProQuad proti ošpicam, mumpsu in rdečkam je bila predhodno dokazana v seriji dvojno slepih, nadzorovanih področnih študij z enovalentnimi cepivi izdelovalca Merck & Co., Inc., ki so dokazale visoko stopnjo učinkovitosti zaščite.
Administration of varicella zoster virus antibody-containing blood products, including VZIG or other immune globulin preparations, within 1 month following a dose of ProQuad may reduce the immune response to the vaccine and hence reduce its protective efficacy. 
Če cepljena oseba v 1 mesecu po cepljenju s cepivom ProQuad dobi krvne pripravke, ki vsebujejo protitelesa proti virusom varicella zoster, vključno z VZIG ali drugimi pripravki imunoglobulinov, lahko to oslabi imunski odziv na cepljenje in zmanjša učinkovitost njegove zaščite.
The safety profiles were comparable for the two different formulations after a single dose. 
Varnostni profili obeh različnih oblik cepiva so bili po enkratnem odmerku primerljivi.
ProQuad may also be administered to infants from 9 months of age under special circumstances (to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles). 
S cepivom ProQuad se lahko v posebnih primerih cepi tudi dojenčke, starejše od 9 mesecev (v skladu z nacionalno shemo cepljenja, v primeru izbruha bolezni ali v primeru potovanja na področje z veliko razširjenostjo ošpic).
Pregnancy Pregnant women should not be vaccinated with ProQuad. 
Nosečnost Nosečnic se ne sme cepiti s cepivom ProQuad.